563 related articles for article (PubMed ID: 18953278)
21. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.
Reffelmann T; Kloner RA
Expert Opin Drug Saf; 2005 May; 4(3):531-40. PubMed ID: 15934858
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Wong P; Lawrentschuk N; Bolton DM
Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase 5 inhibitors: are they cardioprotective?
Reffelmann T; Kloner RA
Cardiovasc Res; 2009 Jul; 83(2):204-12. PubMed ID: 19474180
[TBL] [Abstract][Full Text] [Related]
24. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Proietti M; Aversa A; Letizia C; Rossi C; Menghi G; Bruzziches R; Merla A; Spera G; Salsano F
J Rheumatol; 2007 Aug; 34(8):1712-7. PubMed ID: 17611982
[TBL] [Abstract][Full Text] [Related]
25. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Liu Y
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631
[TBL] [Abstract][Full Text] [Related]
26. [The safety of tadalafil in the treatment of erectile dysfunction].
Wang HY; Huang YF
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):762-4. PubMed ID: 17918720
[TBL] [Abstract][Full Text] [Related]
27. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Kass DA; Champion HC; Beavo JA
Circ Res; 2007 Nov; 101(11):1084-95. PubMed ID: 18040025
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular effects of phosphodiesterase 5 inhibitors.
Reffelmann T; Kloner RA
Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
[TBL] [Abstract][Full Text] [Related]
30. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
31. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
Bella AJ; Deyoung LX; Al-Numi M; Brock GB
Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
[TBL] [Abstract][Full Text] [Related]
32. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study].
Mazo EB; Gamidov SI; Iremashvili VV; Gasanov RV
Urologiia; 2009; (1):40, 43-6. PubMed ID: 19432232
[TBL] [Abstract][Full Text] [Related]
34. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Ghofrani HA; Pepke-Zaba J; Barbera JA; Channick R; Keogh AM; Gomez-Sanchez MA; Kneussl M; Grimminger F
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):68S-72S. PubMed ID: 15194181
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
Francis SH; Morris GZ; Corbin JD
Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.
Jackson G; Montorsi P; Cheitlin MD
Urology; 2006 Sep; 68(3 Suppl):47-60. PubMed ID: 17011375
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Lobo JR; Nehra A
Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
[TBL] [Abstract][Full Text] [Related]
39. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
Porst H
Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
[TBL] [Abstract][Full Text] [Related]
40. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.
Archer SL; Gragasin FS; Webster L; Bochinski D; Michelakis ED
Drugs Aging; 2005; 22(10):823-44. PubMed ID: 16245957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
